May 22, 2025

New FDA-Approved Topical Foam for Scalp Psoriasis

The FDA has approved roflumilast (ZORYVE) foam 0.3% for once-daily treatment of plaque psoriasis in patients aged 12 and older, including hard-to-treat scalp and body areas..

Conexiant

May 22, 2025

Voices on the Go: Top Podcasts for Physicians

Physicians are tuning to podcasts that combine clinical insight, career development, and storytelling.

Conexiant

May 19, 2025

Phase 3 Data Backs Roflumilast Foam

Roflumilast foam was found to improve scalp and body psoriasis symptoms with favorable tolerability in patients aged 12 years and older.

Conexiant

May 19, 2025

Zyrtec and Xyzal: FDA Issues Withdrawal Syndrome Warning

A new safety alert highlights the potential for severe itch following discontinuation of long-term cetirizine and levocetirizine use.

Conexiant

May 19, 2025

Bacteria Eat, Exploit Plastic: Study 

A hospital-derived strain of Pseudomonas aeruginosa was found to degrade medical plastic, use it as food, and form stronger biofilms, revealing new risks for device-related infections.

Conexiant

May 14, 2025

Once-Daily Pill Helps Quell Eczema in Phase 3

Overall, safety findings were consistent with those of other approved JAK1 inhibitors.

Conexiant

May 09, 2025

Psoriasis: Icotrokinra Shows Promise in Late-Stage Trial

Icotrokinra is designed to block a protein, IL-23, involved in inflammatory responses.

Reuters

May 09, 2025

Upper Face Filler Techniques Lack Standardization, Review

A new scoping review revealed significant variation in hyaluronic acid filler injection techniques for the facial upper third.

Conexiant

May 07, 2025

Dr. Vinay Prasad Shakes Up FDA Leadership

The FDA has appointed Vinay Prasad as its new vaccine chief, shaking up biotech stocks and signaling potential shifts in drug approvals.

Reuters